Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep-Oct;7(5):353-61.
doi: 10.5055/jom.2011.0076.

Methadone use in children and young adults at a cancer center: a retrospective study

Doralina L Anghelescu  1 , Lane G Faughnan, Gisele M Hankins, Deborah A Ward, Linda L Oakes
Affiliations

Methadone use in children and young adults at a cancer center: a retrospective study

Doralina L Anghelescu et al. J Opioid Manag. 2011 Sep-Oct.

Abstract

Objective: To augment the literature on methadone applications in pediatric oncology, the authors reviewed the use of methadone at a pediatric cancer center over a 5-year period.

Design and setting: Forty-one patients received methadone for inpatient or outpatient pain management. The authors retrospectively reviewed their demographic characteristics, diagnoses, type of pain (nociceptive, neuropathic, or mixed) and causes of pain, and the indications, dose regimens, adverse effects, and outcomes of methadone treatment.

Results: There were four types of clinical uses for methadone in 41 patients (10 patients had two): nociceptive pain unresponsive to other opioids (17 patients, 33.3 percent), neuropathic pain (20 patients, 39.2 percent), facilitation of weaning from opioids (11 patients, 21.6 percent), and end-of-life pain management (3 patients, 5.9 percent). The mean age of the 24 males (58.5 percent) and 17 females (41.5 percent) at the start of treatment was 15.7 years (range, 0.6-23 years). The most common diagnoses were leukemia (n = 10, 24.4 percent), osteosarcoma (n = 7, 17.0 percent), and rhabdomyosarcoma (n = 5, 12.2 percent). The causes of pain were bone marrow transplant (n = 13, 31.7 percent), amputation (n = 6, 14.6 percent), chemotherapy (n = 5, 12.2 percent), tumor (n = 5, 12.2 percent), limb-sparing surgery (n = 4, 9.8 percent), and other (n = 8, 19.5 percent). Efficacy was assessed at the end (or after 6 months) of methadone treatment. For many patients (43.1 percent), methadone showed efficacy in achieving the purpose for which it was prescribed, including reduction of nociceptive or neuropathic pain and prevention of opioid withdrawal. Sedation was the most common side effect (24.4 percent).

Conclusions: Methadone was effective for pediatric patients with neuropathic pain or nociceptive pain unresponsive to other opioids, and it effectively prevented opioid withdrawal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Duration of methadone treatment in 41 young patients with hematology/oncology.
See this image and copyright information in PMC

References

    1. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev. 2007;(4) CD003971. - PubMed
    1. Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol. 2004;22(1):185–192. - PubMed
    1. Jacob E. Neuropathic pain in children with cancer. J Pediatr Oncol Nurs. 2004;21(6):350–357. - PubMed
    1. Anghelescu D, Oakes L, Popenhagen M. Management of cancer pain in neonates, children and adolescents. In: de Leon-Casasola OA, editor. Cancer Pain: Pharmacological, Interventional and Palliative Care Approaches. 1st ed. Philadelphia: Saunders Elsevier; 2006. pp. 509–521.
    1. Manfredi PL, Houde RW. Prescribing methadone, a unique analgesic. J Support Oncol. 2003;1(3):216–220. - PubMed

Publication types

MeSH terms